FASEB Science Research Conference: Protein Kinases and Protein Phosphorylation
FASEB Science Research Conference: Protein Kinases and Protein Phosphorylation
批准号:
10464756
负责人:
Alex Toker
金额:
$0.35万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-06-01 至 2023-05-31
关键词:
AreaBiochemicalBiochemistryBiological ProcessBiologyCanadaCareer MobilityCellular biologyChemicalsClinicalCollaborationsCommunicationDataDevelopmentDiabetes MellitusDiagnosisDisciplineDiseaseDisease modelDrug IndustryDrug TargetingEducational workshopEventFDA approvedFacultyFertilizationFosteringFundingFutureGoalsGrowth and Development functionHealthHumanInflammationInflammatoryIslandKnowledgeLightingLinkMalignant NeoplasmsMediatingMedicineMentorsMetabolic DiseasesMetabolic syndromeMethodologyMethodsMiningMolecularNormal CellNova ScotiaOncologyPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPlayPreventionPrincipal InvestigatorProcessProtein EngineeringProtein KinaseProtein Kinase Protein PhosphorylationProtein phosphataseProteomeReportingResearchResearch PersonnelRoleScienceScientistSenior ScientistSignal TransductionSiteStructureStructure-Activity RelationshipStudentsSystemSystems BiologyTechnologyTimeTranslational ResearchUnderrepresented MinorityUnderrepresented PopulationsWomancareercareer developmentforgingfrontierhuman diseaseimprovedin vivo Modelinnovationinsightinterestkinase inhibitormeetingsminority scientistmultidisciplinarynext generationnovelnovel anticancer drugnovel therapeuticspostersprogramsrecruitsocialstructural biologysummer researchsymposiumtherapeutic developmenttherapeutic target
中文摘要
项目负责人/主要研究者(最后,第一,中间):Toker,A./班尼特,A.
蛋白质磷酸化在控制细胞状态的分子通讯中至关重要,
活动这是一个由激酶和磷酸酶介导的动态过程,这些激酶和磷酸酶在正常细胞中被精确调节。
在许多人类疾病中,包括糖尿病、炎性疾病和癌症,这种调节是不正常的。研究
蛋白质磷酸化机制及其在信号系统中的功能是一个强大的活性领域,
研究推动了方法和概念的进步,并越来越多地有助于
开发治疗方案。蛋白激酶在癌症中经常失调,并且它们已经被广泛应用于癌症治疗。
制药业最近的关注焦点。事实上,大多数新的癌症药物批准,
在过去的几年里,FDA靶向激酶,并且有数百种新的激酶抑制剂,
发展这种强大的临床联系提供了一个令人兴奋的链接与转化科学。
在此申请中,我们要求资金支持学员,初级教师和传统的出勤率。
2022年FASEB蛋白激酶和蛋白质夏季研究会议
磷酸化。这个两年一度的会议始于1983年,是一个重要的跨学科聚会,
汇集了具有不同专业知识的科学家,以促进对生化机制的理解,
磷酸化活动的基本原则-这一重点使本次会议有别于其他会议,
使用信令网络和系统方法。这次FASEB会议一直是,并将继续是,
宣布该领域突破的地点,并有一个长期的目标,以提高,
传播,知识,将导致改善治疗靶向异常激酶活性,和蛋白质
磷酸化,在人类疾病中。2022年FASEB蛋白激酶科学研究会议
蛋白质磷酸化旨在突出蛋白质磷酸化领域的最新前沿发现,
将结构生物学、生物化学、系统生物学、化学生物学、蛋白质工程和
药这将促进这些通常独立的学科之间的交叉施肥,以刺激新的品系
研究,以及加强沟通,合作,职业发展的不同科学家
在外地最终的目标是推进该领域,以获得更好的理解的分子机制
调节重要的生物学过程并促进诊断的关键目标的识别,
预防、治疗和治愈人类疾病。
OMB编号0925-0001/0002(2018年1月批准至2020年3月31日修订版)页码续页格式页码
英文摘要
Program Director/Principal Investigator (Last, First, Middle): Toker, A./Bennett, A.
Protein phosphorylation is vitally important in the molecular communications that control cellular state and
activity. It is a dynamic process mediated by kinases and phosphatases that are precisely regulated in normal
cells, and deregulated in many human diseases, including diabetes, inflammatory disease and cancer. The study
of the protein phosphorylation machinery and its function in signaling systems is a robustly active area of
research that has driven methodological and conceptual advances and is increasingly contributing to the
development of therapeutic options. Protein kinases are frequently deregulated in cancer, and they have been
the focus of intense recent interest by the pharmaceutical industry. Indeed, most new cancer drugs approved by
the FDA in the last several years target kinases, and there are hundreds of new kinase inhibitors under
development. This strong clinical connection provides an exciting link with translational science.
In this application, we request funds to support attendance of trainees, junior faculty and traditionally
underrepresented groups at the 2022 FASEB Summer Research conference on Protein Kinases and Protein
Phosphorylation. This biennial conference started in 1983, and is an important interdisciplinary gathering that
brings together scientists with diverse expertise to advance understanding of the biochemical mechanisms and
fundamental principles of phosphorylation events – a focus that distinguishes this meeting from others that deal
with signaling networks and systems approaches. This FASEB meeting has been, and continues to be, a primary
venue for the announcement of breakthroughs in the field, and has a long-standing goal to enhance, and
disseminate, knowledge that will lead to improved therapies to target aberrant kinase activity, and protein
phosphorylation, in human disease. The 2022 FASEB Science Research Conference on Protein Kinases and
Protein Phosphorylation aims to highlight recent, cutting-edge findings in the field of protein phosphorylation, to
bring together structural biology, biochemistry, systems biology, chemical biology, protein engineering, and
medicine. This will promote cross-fertilization among these normally separate disciplines to stimulate new lines
of research, as well as to enhance communication, collaboration, career advancement for the diverse scientists
in the field. The ultimate goal is to advance the field to obtain better understandings of the molecular mechanisms
that regulate important biological processes and facilitate the identification of critical targets for the diagnosis,
prevention, treatment, and cure of human diseases.
OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format Page
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer
-
批准号:10246864
-
项目类别:
-
资助金额:$103.5万
-
财政年份:2020
-
负责人:Alex Toker
-
依托单位:
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer
-
批准号:10677761
-
项目类别:
-
资助金额:$97.51万
-
财政年份:2020
-
负责人:Alex Toker
-
依托单位:
Discovery, Regulation and Function of the PI 3-Kinase and AKT Pathway in Cancer
-
批准号:10471296
-
项目类别:
-
资助金额:$100.84万
-
财政年份:2020
-
负责人:Alex Toker
-
依托单位:
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
-
批准号:9903255
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2016
-
负责人:Alex Toker
-
依托单位:
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
-
批准号:9270532
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2016
-
负责人:Alex Toker
-
依托单位:
Identifying lincRNAs that Mediate PI 3 Kinase Dependent Breast Cancer
-
批准号:8610428
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2014
-
负责人:Alex Toker
-
依托单位:
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
-
批准号:9812868
-
项目类别:
-
资助金额:$41.56万
-
财政年份:2013
-
负责人:Alex Toker
-
依托单位:
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
-
批准号:8870311
-
项目类别:
-
资助金额:$36.11万
-
财政年份:2013
-
负责人:Alex Toker
-
依托单位:
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
-
批准号:8559337
-
项目类别:
-
资助金额:$36.11万
-
财政年份:2013
-
负责人:Alex Toker
-
依托单位:
Novel regulation of PI3K/Akt to direct targeted breast cancer therapies
-
批准号:8702122
-
项目类别:
-
资助金额:$35.02万
-
财政年份:2013
-
负责人:Alex Toker
-
依托单位:
FASEB Summer Research Conference on Lipid Signaling Pathways in Cancer
-
批准号:7329084
-
项目类别:
-
资助金额:$0.44万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
-
批准号:8024499
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
-
批准号:7256658
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
-
批准号:7579113
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
-
批准号:7388910
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
The Akt and NFAT Pathway and the Regulaton of Cancer Cell Motility
-
批准号:7772392
-
项目类别:
-
资助金额:$29.07万
-
财政年份:2007
-
负责人:Alex Toker
-
依托单位:
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma
-
批准号:6604523
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2002
-
负责人:Alex Toker
-
依托单位:
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma
-
批准号:6910034
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2002
-
负责人:Alex Toker
-
依托单位:
Role of NFAT and NFAT-Induced Genes in Carcinoma
-
批准号:8055453
-
项目类别:
-
资助金额:$29.52万
-
财政年份:2002
-
负责人:Alex Toker
-
依托单位:
Role of PLCgamma and NFAT Signaling Pathway in Carcinoma
-
批准号:6505993
-
项目类别:
-
资助金额:$30.26万
-
财政年份:2002
-
负责人:Alex Toker
-
依托单位:
海外基金